The CDC revised its pneumococcal pneumonia shot recommendation, saying there is a substantial increase in the risk for ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Pneumococcal shot recommendations are sometimes called the most complicated vaccination guidance that the government issues. The CDC currently recommends shots for children younger than 5 and ...

The vaccine showed promising results in clinical trials. Although the prevention of pneumonia caused by specific pneumococcal ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

If you haven’t received the pneumonia (pneumococcal) vaccine, you’re among the majority of Americans. Just one in four (25%) people at high risk of pneumococcal disease, an infection that ...